Roflumilast in dermatology: Revolutionizing inflammatory skin treatment

Dear Editor, Roflumilast is a selective phosphodiesterase-4 (PDE4) inhibitor that has recently gained attention in dermatology due to its potent anti-inflammatory properties. Initially approved for chronic obstructive pulmonary disease, it has been developed as a topical treatment for inflammatory skin conditions such as plaque psoriasis and seborrheic dermatitis.[1] The FDA approved roflumilast 0.3% cream for psoriasis in July 2022, and the 0.3% foam formulation for seborrheic dermatitis in April 2023.[1] Mechanism of Action PDE4 inhibition leads to an increase in intracellular cyclic adenosine monophosphate, which in turn reduces pro-inflammatory cytokines such as interleukin (IL)-17, IL-23, tumor necrosis factor alpha, and interferon gamma. Compared to apremilast and crisaborole, roflumilast is 25–300 times more potent in inhibiting PDE4, making it a highly effective agent for the dermatological conditions.[1,2] Clinical Applications Plaque psoriasis Psoriatic skin exhibits elevated PDE4 activity, leading to inflammatory cascades that contribute to disease pathogenesis.[1] Clinical trials (DERMIS-1 and DERMIS-2) demonstrated significant efficacy of topical roflumilast 0.3% cream, with 42.4% and 37.5% of patients achieving an Investigator Global Assessment success rate at week 8, compared to 6.1% and 6.9% in the vehicle groups.[3] Unlike corticosteroids, roflumilast can be safely applied to intertriginous areas and is approved for use in patients aged 12 years and older.[1] Seborrheic dermatitis The foam formulation of roflumilast 0.3% has shown promising results for seborrheic dermatitis. A phase II randomized clinical trial demonstrated that it significantly improved disease severity with minimal adverse effects.[1] In addition, roflumilast has antifungal activity, which may contribute to its effectiveness in treating seborrheic dermatitis, as it inhibits yeast PDE activity.[1] Atopic dermatitis A phase II trial assessed the efficacy of roflumilast 0.15% and 0.05% creams for atopic dermatitis, demonstrating a reduction in Eczema Area and Severity Index scores by 6.4 and 6 points, respectively, compared to 4.8 points in the placebo group.[4] Off-label uses Oral roflumilast has shown potential in treating other inflammatory dermatoses: Hidradenitis suppurativa: case reports suggest improvement in severe cases unresponsive to adalimumab and infliximab[1] Recurrent aphthous ulcers: rapid resolution has been observed within 2–3 weeks[1] Erosive lichen planus: improvement was noted after 3 months of treatment[1] Nummular eczema: Complete lesion clearance was reported after 3 months.[1] Safety profile Topical roflumilast has a favorable safety profile, with the most common side effects being mild application site reactions. Systemic adverse effects such as nausea, headache, and diarrhea, commonly seen with oral PDE4 inhibitors, occur at much lower rates with topical formulations.[1,5] Conclusion Roflumilast represents a significant advancement in dermatological therapy. Its superior potency compared to other PDE4 inhibitors, favorable safety profile, and expanding indications make it a valuable addition to the dermatology armamentarium. Future studies will further establish its role in treating inflammatory skin disorders. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.